Topics

Lilly and Incyte's atopic dermatitis drug shows promise at Phase 3

07:17 EST 13 Feb 2020 | Pharmafile

Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib as a treatment for moderate to severe atopic dermatitis in adult patients.

The findings showed that a clinically significant proportion of the trial’s participants taking either 1mg and 2mg doses of baricitinib achieved a change of at least 75% according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment, meeting the primary endpoint of the study.

read more

Original Article: Lilly and Incyte's atopic dermatitis drug shows promise at Phase 3

NEXT ARTICLE

More From BioPortfolio on "Lilly and Incyte's atopic dermatitis drug shows promise at Phase 3"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...